CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
Intravitreal dexamethasone implantdrug
Likely dose
Intravitreal dexamethasone implant 0.7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05736081
NCT05736081Phase 4Completed
CompareCT.gov

Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

Asociación para Evitar la Ceguera en México·interventional·Posted Feb 21, 2023·Updated Aug 2, 2024

In Brief

A Phase 4 clinical trial evaluating Intravitreal dexamethasone implant for Diabetic Macular Edema. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The goal of this clinical trial es to learn about the short term effects of intravitreal dexamethasone implant (IDI) in patients with refractory diabetic macular edema. The main question it aims to answer is: How fast does the diminishing in central retinal thickness has statistical significance after IDI in patients with refractory diabetic macular edema? Patients will be evaluated by OCT before and after the implant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesMexico
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedFeb 21, 2023
Enrollment StartFeb 15, 2018
Primary CompletionJun 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.4 years ago

Interventions

Intravitreal dexamethasone implantdrug

Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops